Hikma Pharmaceuticals Share News (HIK)

Hikma Pharmaceuticals shoots higher as Barclays hails Roxane deal

(ShareCast News) - Hikma Pharmaceuticals got a shot in the arm on Wednesday as Barclays lifted its price target on the stock to 2,760p from 2,050p. The bank said Hikma has transformed its US exposure and long-term visibility through the $2.65bn acquisition of US specialty generics company Roxane. "

LONDON MARKET MIDDAY: US Stocks Called To Rebound With Data In Focus

WINNERS & LOSERS SUMMARY: Halfords Knocked Off Its Bike

BUZZ-Hikma: 2nd top FTSE gainer after Barclays lauds Boehringer deal

** Pharma co Hikma up c.5.6 pct, 2nd top gainer on London's bluechip index & on track for sharpest move in over 1 mnth after brokerage TP hike ** Barclays says U.S. generics deal, announced in July, transforms Hikma's long-term growth profile and ups TP on stock to 2760p from 2050p, keeps "

LONDON MARKET OPEN: Ashtead Shares Rise After Impressive First Quarter

LONDON BRIEFING: Ashtead And Hikma Lead Positive Early Market

DIRECTOR DEALINGS SUMMARY: Four FTSE 100 Directors Buy Shares

DIRECTOR DEALINGS: Hikma Non-Executive Director Buys First Shares

Ex-divs to take 1.37 points off FTSE 100 on Aug. 27

LONDON, Aug 24 (Reuters) - The following FTSE 100 companies will go ex-dividend on Thursday, after which investors will no longer qualify for the latest dividend payout. According to Reuters calculations at current market prices, the effect of the resulting adjustment to prices by market-mak

DIRECTOR DEALINGS: Hikma Pharmaceuticals Director Sells 22,000 Shares

LONDON MARKET CLOSE: September US Rate Hike Still Seen On Despite Data

FTSE 100 movers: Glencore drags blue chips lower

(ShareCast News) - Following the downbeat overnight sessions elsewhere, the FTSE 100 shot lower in early trade and by the afternoon had failed to crawl higher. By 1545, the blue chip index was down 1.35% at 6,438.07 points, with only a dozen companies' shares in positive territory. Leading the fall

LONDON MARKET MIDDAY: Stocks Weak Ahead Of US Inflation, Fed Minutes

BUZZ-Hikma: Keeps guidance intact despite revenue drop

** Hikma rises as much as 5 pct to 2520 pence after co maintains FY guidance, making them the second highest FTSE-100 gainers ** Shares rise to highest in almost 6 months, with 70 pct of avg 30-day volumes going through in first 3 hours ** Stock is also number 3 gainer on Europe's ben

WINNERS & LOSERS SUMMARY: Admiral And Hikma Up But Glencore Plunges